Behavioral effects of clomipramine on prepubertal boys with autistic disorder and severe mental retardation

CNS Spectrums

Volumn 3, Issue 10, 1998, Pages 39-46

  Brasic, James Robert ^a   Barnett, Jacqueline Y ^b   Sheitman, Brian B ^c   Todd Lafargue, R ^d   Kowalik, S ^e   Kaplan, Diana ^a   Tsaltas, Margaret Owen ^f   Ahmad, Raheela ^a   Nadrich, Robert H ^a   De Mendonça, Maria Fatima ^a  

^a BELLEVUE HOSPITAL CENTER   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Dorothea Dix Hospital   (United States)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^e NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^f THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOMIPRAMINE;

AUTISM; CLINICAL ARTICLE; DRUG EFFECT; HUMAN; MALE; MENTAL DEFICIENCY; NEUROTOXICITY; PRIORITY JOURNAL; REVIEW; SCORING SYSTEM;

EID: 0032461306     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1092852900006647     Document Type: Review

References (93)

1. Campbell M, Overall JE. Diagnostic criteria and behavior patterns in infantile autism. Psychopharmacol Bull. 1989;25:194-197.
2. Rutter M. The treatment of autistic children. / Child Psychol Psychiatry. 1985;26:193-214.
3. Anderson LT, Campbell M, Grega DM, Perry R, Small AM, Green WH. Haioperidol in the treatment of infantile autism: effects on learning and behavioral symptoms. /1m J Psychiatry. 1984;141:1195-1202.
4. Anderson LT, Campbell M, Adams P, Small AM, Perry R, Shell J. The effects of haloperidol on discrimination learning and behavioral symptoms in autistic children. J Autism Dev Disord. 1989;19:227-239.
5. Campbell M. Stereotypies and tardive dyskinesia: abnormal movements in autistic children. Psychopharmacol Bull 1990;26:260-266.
6. Campbell M, Adams P, Perry R, Spencer EK, Overall JE. Tardive and withdrawal dyskinesia in autistic children: a prospective study. Psychopharmacol Bull. 1988;24:251-255.
7. Hytlel J. Serotonin uptake inhibitors. In: Paoletti R, Vanhoute PM, Brunello N, Maggi FM, eds. Serotonin: From Cell Biology to Pharmacology and Therapeutics. Nonvell, Massachusetts: Kluwer Academic Publishers; 1990:459-461.
8. BrasicJR, Barnett JY, Sheitman BB, Tsaltas MO. Adverse effects of clomipramine [letter]. J Am Acad Child Adolesc Psychiatry. 1997;36:1165-1166.
9. Wilens TE, Steingard R, Biederman J. Clomipramine for comorbid conditions [letter]. J Am Acad Child Adolesc Psychiatry. 1992;31:171.
10. Austin LS, Lydiard RB, Ballenger JC, et al. Dopamine blocking activity of clomipramine in patients with obsessive-compulsive disorder. Biol Psychiatry. 1991;30:225-232.
11. Cohen DJ, Caparulo BK, Shaywitz BA, Bowers MB. Dopamine and serotonin metabolism in neuropsychiatrically disturbed children. Arch Gen Psychiatry. 1977;3J:545-550.
12. Young JG, Kavanagh ME, Anderson GM, Shaywitz BA, Cohen DJ. Clinical neurochemistry of autism and associated disorders. J Autism Dei- Disord. 1982;12:147-165.
13. Schain RJ, Freedman DX. Studies on 5-hydroxyindole metabolism in autistic and other mentally retarded children. J Pediatrics. 1961;58:315-320.
14. Ril'vo ER, Yuwiler A, Geller E, Ornitz E, Saeger K, Plotkin S. Increased blood serotonin and platelets in early infantile autism. AMA Archites of General Psychiatry. 1970;23:566-572.
15. Campbell M, Friedman E, DeVito E, Greenspan L, Collins PJ. Blood serotonin in psychotic and braindamaged children. Journal of Autism and Childhood Schizophrenia. 1974;4:33-41.
16. Anderson CM, Freedman DX, Cohen DJ, et al. Whole blood serotonin in autistic and normal subjects. / Child Psychol Psychiatry. 1987;28:885-900.
17. Yuwiler A, Freedman DX. Neurotransmitter research in autism. In: Schopler E, Mesibov GB, eds. i\eurobiological Issues in Autism. New York, New York: Plenum; 1987:263-284.
18. Cook EH. Autism: review of neurochemical investigation. Synapse. 1990;6:292-308.
19. Fuller RW, Wong DT. Serotonin uptake and serotonin uptake inhibition. Ann NYAcadSci. 1990;600:68-78.
20. Clomipramine Collaborative Study Group. Clomipramine in the treatment of patients with obsessive-compulsive disorder. Arch Gen Psychiatry. 1991;48:730-738.
21. Insel TR, Murphy GL, Cohen RM, Alterman I, Kilts D, Linnoila M. Obsessive-compulsive disorder: a doubleblind trial of clomipramine and clorgyline. Arch Gen Psychiatry. 1983;40:605-612.
22. Katz RJ, DeVeaugh-Geiss J, Landau P. Clomipramine in obsessive-compulsive disorder. Biol Psychiatry. 1990;28:401-414.
23. Mavissakalian M, Jones, B, Oison S, Perel JM. The relationship of plasma clomipramine and N'-desmethylclomipramine to response in obsessive-compulsive disorder. Psychopharmacol Bull. 1990;26:119-122.
24. DeVeaugh-Geiss J, Moroz G, Biederman J, et al. Clomipramine hydrochloride in childhood and adolescent obsessive-compulsive disorder-a mullicenter trial. JAm Acad Child Adolesc Psychiatry. 1992;31:45-49.
25. Fallon BA, Campeas R, Schneier FR, et al. Open trial of intravenous clomipramine in five treatment-refractory patients with obsessive-compulsive disorder. J i\europsychiatry Clin Ncurosci. 1992;4:70-75.
26. Insel TR. Neurobiology of obsessive-compulsive disorder: a review. Int Clin Psychopharmacol. 1992;7 (suppl l):31-33.
27. Ratzoni G, Hermesh H, Brandt N, Lauffer M, Munitz H. Clomipramine efficacy for tics, obsessions, and compulsions in Tourette's syndrome and obsessivecompulsive disorder: a case study. Biol Psychiatry. 1990;27:95-98.
28. Brasic JR, Barnett JY, Kaplan D, et al. Clomipramine ameliorates adventitious movements and compulsions in prepubertal boys with autistic disorder and severe mental retardation. Neurology. 1991;44:1309-1312.
29. Wong CM, Hollander E. New dimensions in the OCD spectrum: autism, pathologic gambling, and compulsive buying. Primary Psychiatry. 1996;3:20-34.
30. Hollander E, Wong C. Developments in the treatment of obsessive-compulsive disorder. Primary Psychiatry. 1995:2:28-33.
31. Fraser AD, Bryan W, Isner AF. Evaluation of the EMIT amitriptyline and norlriptyline assays for the determination of serum clomipramine and desmethylclomipramine. Ther DrugMonit. 1989;ll:349-353.
32. Vazquez Rodriguez AM, Arranz Peiia MA, Lopez Ibor JJ, et al. Clomipramine test: serum level determination in three groups of psychiatric patients. J Pharm Biomed Anal. 1991;9:949-952.
33. Cook EH, Rowlett R, Jaselskis C, Leventhal BL. Fluoxetine treatment of children and adults with autistic disorder and mental retardation. J Am Acad Child Adolesc Psychiatry. 1992;31:739-745.
34. Campbell M, Cueva JE. Psychopharmacology in child and adolescent psychiatry: a review of the past seven years. Part I. J Am Acad Child Adolesc Psychiatry. 1995;34:1124-1132.
35. Gordon CT, Rapoport JL, Hamburger SD, State RC, Mannheim GB. Differential response of seven subjects with autistic disorder to clomipramine and desipramine. Arn J Psychiatry. 1992;149:363-366.
36. McDougle CJ, Price LH, Volkmar FR, Goodman WK, Ward-0'Brien D, Nielsen J, Bregman J, Cohen DJ. Clomipramine in autism: preliminary evidence of efficacy. J Am Acad Child Adolesc Psychiatry. 1992;31:746-750.
37. Garher HJ, McGonigle JJ, Slomka GT, Monteverde E. Clomipramine treatment of Stereotypie behaviors and self-injury in patients with developmental disabilities. J Am Acad Child Adolesc Psychiatry. 1992;31:1157-1160.
38. Barlas S. N1MH researchers find clomipramine helps autism. Psychiatric Times. 1993;10(8):10.
39. Gordon CT, State RC, Nelson JE, Hamburger SD, Rapoport JL. A double-blind comparison of clomipramine, desipramine, and placebo in the treatment of autistic disorder. Arch Gen Psychiatry. 1993;50:441-447.
40. Markowitz PI. Effect of fluoxetine on self-injurious behavior in the developmental!)' disabled: a preliminary study. / Clin Psychopharmacol. 1992;12:27-31.
41. Hollander E, Wong CM. Introduction. Obsessive-compulsive spectrum disorders. J Clin Psychiatry. 1995;56(suppl 4):3-6.
42. BrasiS JR, Barnett JY, Aisemberg P, et al. Dyskinesias subside off all medication in a boy with autistic disorder and severe mental retardation. Psychol Rep. 1997;81:755-767.
43. Rosenquist PB, Bodfish JW. Neuropsychiatrie movement disorders in those with mental retardation or developmental disability. Psychiatric Annals. 1997;27:213-218.
44. Balant-Gorgia AE, Balant LP, Garrone G. High blood concentrations of imipramine or clomipramine and therapeutic failure: a case report study using drug monitoring data. Ther Drug Monit. 1989;! 1:415-420.
45. Gouezo F, Rop PP, Viala A. Influence du sexe et du tabagisme sur les concentrations plasmatiques de la clomipramine, de l'amitriptyline et de leurs metabolites déméthylés [Influence of sex and tobacco use on the plasma concentrations of clomipramine, amitriptyline, and their desmethylated metabolites]. Journal de Toxicologie Clinique et Expérimentale. 1988;8:39-46.
46. Meiselas KD, Spencer EK, Oberfield R, Peselow ED, Angrist B, Campbell M. Differentiation of stereotypies from neuroleplic-related dyskinesias in autistic children. / Clin Psychopharmacol. 1989;9:207-209.
47. Schwartz SS, Galagher RJ, Berkson G. Normal repetitive and abnormal stereotyped behavior of nonretarded infants and young mentally retarded children. American Journal of Mental Deficiency. 1986;90:625-630.
48. Wehmeyer ML. Typical and atypical repetitive motor behaviors in young children at risk for severe mental retardation. Am J Ment Retard. 1991;96:53-62.
49. Brasic JR, Barnett JY, Sheitman BB, Lafargue RT, Aim SC. Clinical assessment of adventitious movements. Psychol Rep. 1998;83:723-73-t.
50. Kim SW, Dysken M\V. Test of dopamine-blocking potential of clomipramine [letter]. Am J Psychiatry. 1991:148:690.
51. Benkelfat C, Murphy DL, Zohar J, Hill JL, Graver G, Insel TR. Clomipramine in obsessive-compulsive disorder: further evidence for a serotonergic mechanism of action. Arch Gen Psychiatry. 1989;46:23-28.
52. Sanchez LE, Campbell M, Small AS, Cueva JE, Armenleros JL, Adams PB. A pilot study of clomipramine in young autistic children. J Am Acad Child Adolesc Psychiatry. 1996 5:537-5 W.
53. Riddle MA, Geller B, Ryan N. Another sudden death in a child treated with desipramine. J Am Acad Child Adolesc Psychiatry. 1993;32:792-797.
54. Rartels MG, Varley CK, Mitchell J, Stamm SJ. Pédiatrie cardiovascular effects of imipramine and desipramine. J Am Acad Child Adolesc Psychiatry. 1991 0:100-103.
55. Biedemian J, Baidessarini RJ, Goldblatt A, Lapey KA, Doyle A, Hesslein PS. A naturalistic study of 24-hour electrocardiographic recordings and echocardiographic findings in children and adolescents treated with desipramine. J Am Acad Child Adolesc Psychiatry. 1993:32:805-813.
56. Fetner HI1, Geller B. Lithium and tricyclic antidepressants. Psychialr Clin North Am. 1992;! 5:223-241.
57. Wilens TE, Biedemian J, Baldessarini RJ, Puopolo PR, Flood JG. Electrocardiographic effects of desipramine and 2-hydroxydesipramine in children, adolescents, and adults treated with desipramine. J Am Acad Child Adolesc Psychiatry. 1993;32:798-801.
58. Preskorn SH, Jerkovich GS. Central nervous system toxicîty of tricyclic antidepressants: phenomenology, course, risk factors, and role of therapeutic drug monitoring. J Clin Psychopharmacol. 1990; 10:88-95.
59. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 3rd ed., rev. Washington, DC: American Psychiatric Association; 1987.28-39.
60. Munetz MR, Benjamin S. How to examine patients using the abnormal Involuntary Movement Scale. Hospital and Community Psychiatry. 1988;39:1172-1177.
61. Sanchez LE, Adams PB, Uysal S, Hallin A, Campbell M, Small AM. A comparison of live and videotaped ratings: clomipramine and haloperidol in autism. Psychopharmacol Bull. 1995;31:371-378.
62. Guy W. Clinical Global Impressions. ECDEU Assessment Manual for Psychopharmacology; Revised, 1976. (DHEW Publication No. (ADM) 76-338.) Rockville, Maryland: United Staled Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration; 1976:217-222.
63. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 3rd ed. Washington, DC: American Psychiatric Association; 1980:41-45.
64. Leckman JF, Towbin KE, Ort SI, Cohen DJ. Clinical assessment of tic disorder severity. In: Cohen DJ, Bruun RD, Leckman JF, eds. Tourctle's Syndrome & Tic Disorders. New York, New York: John Wiley & Sons; 1988:55-78.
65. Fish B. Children's Psychiatric Rating Scale. Psychopharmacol Bull. 1985;21:753-770.
66. Kay SR, Wolkenfeld F, Murrill LM. Profiles of aggression among psychiatric patients: I. Nature and prevalence. J Nerv Ment Dis. 1988;176:539-516.
67. Shaffer D, Gould MS, Brasic J, Ambrosini P, Fisher P, Bird H, Aluwahlia S. A Children's Global Assessment Scale (CGAS) (for children 4 to 16 years of age). Psychopharmacol Bull. 1985;21:747-748.
68. Adler LA, Duncan E, Kirn A, Hemdal P, Rotrosen J, Angrist B. Akathisia: selective - blockers and rating instruments. Psychopharmacol Bull. 1989;25:451-456.
69. Lipinski JF, Keck PE, McElroy SL. -adrenergic antagonists in psychosis: is improvement due to treatment of neuroleptic-induced akathisia? J Clin Psychopharmacol. 1988;8:409-416.
70. Conover WJ. The one-sample or matched pairs case. Practical Nonparametric Statistics. 2nd ed. New York, New York: John Wiley & Sons; 1980:278-294.
71. Brasic JR, Bamett JY, Ahn SC, Nadrich RH, Will MV, Clair A. Clinical assessment of self-injurious behavior. PsycholRep. 1997;80;155-160.
72. BrasicJR, Barnett JY, Sheitman BB, et al. Clomipramine enhances adaptive behavior in autistic boys [abstract]. 9th World Congress of Psychiatry Abstracts, Rio de Janeiro, Brazil, June 6-12,1993.1993:76, Abstract 298.
73. Brasic JR, Barnett JY. Hyperkinesias in a prepubertal boy with autistic disorder treated with haloperidol and valproic acid. Psychol Rep. 1997;80:163-170.
74. Mikkelsen EJ, Albert LG, Emens M, Rubin E. The efficacy of antidepressant medication for individuals with mental retardation. Psychiatric Annals. 1997;27:198-206.
75. Botstein P. Is QT interval prolongation harmful? A regulatory perspective. Am J Cardiol. 1993;72(6):50B-52B.
76. Lipicky RJ. A viewpoint on drugs that prolong the QTc interval. Am J Cardiol. 1993;72(6):53B-54B.
77. Tïngelstad JB. The cardiotoxicity of the tricyclics. J Am Acad Child Adolesc Psychiatry. 1991;30:845-816.
78. Riddle MA, Nelson JC, Kleinman CS, et al. Sudden death in children receiving Norpramin: a review of three reported cases and commentary. J Am Acad Child Adolesc Psychiatry. 1991;30:104-108.
79. Geller B. Commentary on unexplained deaths of children on Norpramin. J Am Acad Child Adolesc Psychiatry. 1991;30:682-683.
80. Kasvikis Y, Marks I. Clomipramine in obsessive-compulsive ritualisers treated with exposure therapy: relations between dose, plasma level, outcome and side effects. Psychopharmacology. 1988;95:113-118.
81. Kutcher SP. Child and Adolescent Psychopharmacology. Piiiladelphia, Pennsylvania; W. B. Saunders Company; 1997.
82. Whelan AJ. Patient care in internal medicine. In: Ewald GA, McKenzie CR, eds. Manual of Medical Therapeutics. 28lh ed. Boston, Mass: Little, Brown and Company; 1995:1- 28.
83. Sternbach H. The serotonin syndrome. Am J Psychiatry. 1991;148:705-713.
84. Sussman N. The potential benefits of serotonin receptor-specific agents. / Clin Psychiatry. 1994;55(2 part 3, suppl):45-51.
85. Geller DA, Biederman J, Reed ED, Spencer T, Wilens TE. Similarities in response to fluoxetine in the treatment of children and adolescents with obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry. 1995;34:36-44.
86. Leo RJ. Movement disorders associated with the serotonin selective reuptake inhibitors. J Clin Psychiatry. 1996;57:449-454.
87. Wilde MI, Plosker GL, Benfield P. Fluvoxamine: an updated review of its pharmacology, and therapeutic use in depressive illness. Drugs. 1993;46:895-924.
88. Brasic JR, Young JG. Research design, measures, and statistics. In: Robson KS, ed. Manual of Clinical Child and Adolescent Psychiatry. Rev. ed. Washington, DC: American Psychiatric Press, Inc.; 1994:435-463.
89. Richelson E. Pharmacokinetic drug interactions of new antidepressanls: a review of the effects on the metabolism of other drugs. Mayo Clin Proc. 1997;72;835-847.
90. Altamura AC. The clinical use of anticholinergic drugs in neuroleptic induced extrapyramidal side-effects. A controversial issue. In: Nappi G, Hornykiewicz 0, Fariello RG, Agnoli ; A, Klawans H, eds. Neiirodegeneratiie Disorders: The Role Played by Endotoxins and Xenobiolics. New York, NY: Raven Press; 1988:179-192.
91. Campbell M, Adams PB, Small AM, et al. Lithium in hospitalized aggressive children with conduct disorder: a double-blind and placebo-controlled study. J Am Acad Child Adolesc Psychiatry. 1995;34:445-453.
92. Briley M, Morel C. 5-HT and antidepressants: in vitro and in vivo release studies [letter]. Trends Pharmacol Sei. 1993;14:396-397.
93. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994:83-85.